These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27377908)

  • 1. Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
    Yim HJ
    Clin Mol Hepatol; 2016 Jun; 22(2):238-40. PubMed ID: 27377908
    [No Abstract]   [Full Text] [Related]  

  • 2. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
    DING JG; SUN QF; FU RQ; WU YH; HONG L
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209
    [No Abstract]   [Full Text] [Related]  

  • 3. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
    Berg T; Zoulim F; Moeller B; Trinh H; Marcellin P; Chan S; Kitrinos KM; Dinh P; Flaherty JF; McHutchison JG; Manns M
    J Hepatol; 2014 Apr; 60(4):715-22. PubMed ID: 24295873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
    Park JH; Jung SW; Park NH; Park BR; Kim MH; Kim CJ; Lee BU; Jeong ID; Kim BG; Bang SJ; Shin JW
    Clin Ther; 2015 Jul; 37(7):1433-42. PubMed ID: 25956353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
    Kim SB; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    J Gastroenterol Hepatol; 2016 Jan; 31(1):241-7. PubMed ID: 26204913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Leclerc L; Martinot-Peignoux M; Matheron S; Marcellin P
    Antivir Ther; 2012; 17(1):61-70. PubMed ID: 22267470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
    Kim BG; Jung SW; Kim EH; Kim JH; Park JH; Sung SJ; Park BR; Kim MH; Kim CJ; Lee BU; Park JH; Jeong ID; Bang SJ; Shin JW; Park NH
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1514-21. PubMed ID: 25973716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
    Cho HJ; Kim SS; Shin SJ; Yoo BM; Cho SW; Cheong JY
    J Med Virol; 2015 Sep; 87(9):1532-8. PubMed ID: 25940352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.